SCHEMBL22982006

SCHEMBL22982006

CCCC[C]1C=Cc2cc3ccccc3cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.37
PSMB5 P28074 1/20 0.35
NPC1 O15118 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
BCHE P06276 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP2A6 P11509 1/20 0.32
LMNA P02545 2/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPT P10636 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
GPR84 Q9NQS5 1/20 0.31
OXER1 Q8TDS5 1/20 0.31
ABCB11 O95342 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23273292 0.95 TLR8 (0.39) TLR8NPC1MEN1KMT2AATM
SCHEMBL22982645 0.93 KCNH2 (0.40) TLR8MAPTGPR84KCNH2
SCHEMBL28762177 0.93 KCNH2 (0.40) TLR8MAPTGPR84KCNH2
SCHEMBL22982174 0.93 KCNH2 (0.40) TLR8MAPTGPR84KCNH2
SCHEMBL22982483 0.89 CYP1A2 (0.34) MEN1KMT2AATMCYP1A2CYP2A6
SCHEMBL22982022 0.82 CYP2A6 (0.41) CYP1A2CYP2A6MAPTTDP1
SCHEMBL219213 0.78 SETD7 (0.42) NPC1MEN1KMT2ABCHECYP1A2
SCHEMBL22982469 0.77 KCNH2 (0.37) NPC1CYP1A2CYP2A6RAB9ASMN1; SMN2
SCHEMBL28573966 0.77 SETD7 (0.41) NPC1MEN1KMT2ABCHECYP1A2
SCHEMBL28818349 0.77 SETD7 (0.41) NPC1MEN1KMT2ABCHECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-05-30 US disclosed
CN-114845980-A Dimer-selective metallocene catalyst, non-aromatic hydrocarbon soluble activator and method for preparing poly alpha-olefin oligomer using the same 埃克森美孚化学专利公司 2022-08-02 CN disclosed
EP-4010385-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS ExxonMobil Chemical Patents Inc. (US) 2022-06-15 EP disclosed
CN-114502521-A Process for producing low viscosity polyalphaolefins using non-aromatic hydrocarbon soluble activators 埃克森美孚化学专利公司 2022-05-13 CN disclosed
WO-2021086926-A1 DIMER SELECTIVE METALLOCENE CATALYSTS, NON-AROMATIC HYDROCARBON SOLUBLE ACTIVATORS, AND PROCESSES TO PRODUCE POLY ALPHA-OLEFIN OLIGMERS THEREWITH EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-05-06 WO disclosed
US-20210122859-A1 Dimer Selective Metallocene Catalysts, Non-Aromatic Hydrocarbon Soluble Activators, And Processes To Produce Poly Alpha-Olefin Oligmers Therewith EXXONMOBIL CHEMICAL PATENTS INC (US) 2021-04-29 US disclosed
WO-2021030045-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith NONO, TPR, ZNF787 TLR8 1915/4885PSMB5 531/4885NPC1 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.